Effects of Pioglitazone in Hypertensive Patients

Effects of Pioglitazone and Glimepiride in Hypertensive Patients - Relationship With AGE, Inflammatory Cytokines and Cardiac Markers -

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01472497

Enrollment

Registered

2011-11-16

Start date

2007-04-30

Completion date

2012-03-31

Last updated

2012-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Insulin Resistance

Keywords

hypertension, insulin resistance, oral glucose tolerance test, AGE, inflammatory cytokine

Brief summary

Insulin resistance is often complicated with hypertension. AGE and inflammation play important roles in insulin resistance. Some studies reported that pioglitazone, insulin sensitizer, is effective for patients with insulin resistance, however, the mechanisms are still unclear. The aim of this study to evaluate the effect of pioglitazone compared with glimepiride on AGE, inflammatory cytokines and cardiac markers (BNP and echo) in hypertensive patients during oral glucose tolerance test.

Interventions

DRUGPioglitazone

pioglitazone (15mg) once a day for 24 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Hypertension with insulin resistance

Exclusion criteria

* Chronic systolic heart failure, ACS

Design outcomes

Primary

Measure	Time frame
advanced glycation end-product (AGE)	24 weeks
inflammatory cytokines (TNF-alfa, IL-6 and MCP-1)	24 weeks
cardiac function (echo and BNP)	24 weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026